Applied Evidence

Strategies for caring for the well cancer survivor

Author and Disclosure Information

 

References

Radiation therapy to the chest leads to many cardiac complications, including cardiomyopathy, valvular disease, pericardial disease, and arrhythmias. Development of cardiomyopathy can be delayed 20 to 30 years after radiation; screening echocardiography is therefore recommended every 5 to 10 years after radiation therapy.65 Recent adjustments to the dosages and delivery of radiation therapy should reduce cardiac damage, but will require decades to validate.63

Evidence is accumulating that chronic opioid therapy exacerbates chronic pain.

For patients at risk of cardiovascular disease prior to treatment of cancer, there is evidence to support preventive treatment with angiotensin II-receptor antagonists, beta-blockers, and statins to prevent cardiomyopathy.63 Treatment of diagnosed cardiomyopathy and heart failure follows standard guidelines, with significant emphasis on aerobic exercise and smoking cessation.63

Cancer survivorship care: Your critical role

Cancer survivors constitute a large population who frequent the practices of primary care physicians. Primary care visits provide an opportunity to monitor key elements of survivorship, including surveillance of the current cancer and screening for second cancers. Similar to what is seen with diabetes and coronary artery disease, cancer increases cardiac risk, which requires preventive care and chronic management. FPs are well placed to treat common issues in cancer survivors—issues that mirror concerns seen in the general population.

CORRESPONDENCE
Michael J. Arnold, MD, CDR, USN, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814; michael.arnold@usuhs.edu.

ACKNOWLEDGEMENT
Kristian Sanchack, MD, and James Higgins, DO, assisted with the editing of the manuscript.

Pages

Recommended Reading

When is the right time to stop treatment?
Journal of Clinical Outcomes Management
More biosimilars reach the market in efforts to improve access and cut costs
Journal of Clinical Outcomes Management
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression
Journal of Clinical Outcomes Management
Hormonal contraceptive use linked to leukemia risk in offspring
Journal of Clinical Outcomes Management
STORM trial shows response in penta-refractory myeloma
Journal of Clinical Outcomes Management
ASCO addresses financial barriers to cancer clinical trials
Journal of Clinical Outcomes Management
Researchers propose new acute leukemia subtypes
Journal of Clinical Outcomes Management
Adjuvant Pembrolizumab Improves Progression-Free Survival in Stage III Melanoma
Journal of Clinical Outcomes Management
Nocturnal Dexmedetomidine for Prevention of Delirium in the ICU
Journal of Clinical Outcomes Management
Polycythemia Vera and Essential Thrombocythemia
Journal of Clinical Outcomes Management